It is expected to be approved soon
Retatrutide (Phase 2, NEJM 2023) Published in The New England Journal of Medicine , the Phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) enrolled 338 adults and demonstrated dose-dependent weight reduction
As your body adjusts, you may notice steady progress in your weight loss journey
Proof-first summary Researcher selection highlights Strength range 10mg / 15mg / 20mg Variant selection keeps Retatrutide strength labels tied to batch and stock context
In April 2005 the US Food and Drugs Administration (FDA) approved a synthetic version, called exenatide, to treat type 2 diabetic patients unable to sufficiently control their blood sugar levels with other diabetic medications like metformin, and sulfonylureas
If hives are widespread or accompanied by other symptoms (swelling of the face or throat, difficulty breathing, rapid heartbeat), seek emergency medical attention immediately